Unicycive Therapeutics, Inc. (UNCY) Dividend History

Unicycive Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for liver and kidney diseases. The company's portfolio includes innovative therapies aimed at addressing unmet medical needs in chronic liver and renal conditions. Unicycive aims to leverage its expertise in drug development to improve patient outcomes.

4300 El Camino Real, Suite 210, Los Altos, CA, 94022
Phone: 650-384-0642
Website: https://www.unicycive.com

Dividend History

Unicycive Therapeutics, Inc. currently does not pay dividends

Company News

Unicycive Therapeutics to Present at Upcoming Investor Conferences

Unicycive Therapeutics, a clinical-stage biotechnology company, announced that its CEO will present at two upcoming virtual investment conferences in May and June 2025.

GlobeNewswire Inc.
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics, a clinical-stage biotechnology company, announced that its CEO will present at the 24th Annual Needham Virtual Healthcare Conference. The company's lead drug candidate, oxylanthanum carbonate (OLC), is under review by the FDA for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

GlobeNewswire Inc.
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Unicycive Therapeutics published a review on patient perspectives regarding phosphate management, highlighting key barriers to effective phosphorus management and the need for patient-centered approaches to improve clinical outcomes and patient satisfaction.

GlobeNewswire Inc.
Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

Unicycive Therapeutics announced that the FDA has accepted its NDA for Oxylanthanum Carbonate (OLC), a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis. The FDA has set a PDUFA action date of June 28, 2025, and Unicycive is preparing for a potential commercial launch in the second half of 2025 if the drug is approved.

GlobeNewswire Inc.
Unicycive Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference - GlobeNewswire

Unicycive Therapeutics, a clinical-stage biotechnology company, announced that its CEO will participate in a fireside chat at the H.C. Wainwright 3rd Annual Kidney Virtual Conference.

GlobeNewswire Inc.

Dividend data last updated 06/07/2025 20:42:23 UTC